SCHEMBL3767486

SCHEMBL3767486

Cc1ccc(CC(=O)N2CCN(CC(=O)N3CCN(C4CCC4)CC3)CC2)cc1

nearest known ligand 0.61

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.61
KDM4E B2RXH2 3/20 0.61
SMN1; SMN2 Q16637 2/20 0.55
LMNA P02545 1/20 0.55
POLB P06746 2/20 0.53
KMT2A Q03164 2/20 0.52
MEN1 O00255 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.49
TSHR P16473 1/20 0.46
GFER P55789 1/20 0.46
USP2 O75604 1/20 0.46
CYP2C19 P33261 2/20 0.46
HPGD P15428 1/20 0.46
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3774201 0.88 ALDH1A1 (0.61) ALDH1A1KDM4ESMN1; SMN2POLBKMT2A
SCHEMBL3770031 0.88 KDM4E (0.61) ALDH1A1KDM4ESMN1; SMN2KMT2AMEN1
SCHEMBL3775691 0.88 ALDH1A1 (0.61) ALDH1A1KDM4ESMN1; SMN2LMNAKMT2A
SCHEMBL3770129 0.88 ALDH1A1 (0.80) ALDH1A1KDM4ESMN1; SMN2LMNAKMT2A
SCHEMBL3774279 0.87 ALDH1A1 (0.57) ALDH1A1KDM4ESMN1; SMN2KMT2ATSHR
SCHEMBL3768080 0.87 ALDH1A1 (0.57) ALDH1A1KDM4ESMN1; SMN2KMT2AMEN1
SCHEMBL3777237 0.87 SMN1; SMN2 (0.64) ALDH1A1KDM4ESMN1; SMN2LMNAKMT2A
SCHEMBL3774399 0.86 POLB (0.62) ALDH1A1KDM4ESMN1; SMN2LMNAPOLB
SCHEMBL3772641 0.86 ALDH1A1 (0.69) ALDH1A1KDM4ESMN1; SMN2LMNATSHR
SCHEMBL3766156 0.85 USP2 (0.62) ALDH1A1KDM4EPOLBL3MBTL1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 ALDH1A1 1210/4885KDM4E 534/4885SMN1; SMN2 4282/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.